Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes (APCam05)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Children and adolescents with type 1 diabetes need regular insulin injections or continuous insulin delivery with an insulin pump in order to keep blood sugar levels normal. The investigators know that keeping blood sugars in the normal range can prevent long term diabetes complications involving the eyes, kidneys and heart. However, achieving treatment goals can be very difficult as the tighter the investigators try to control blood glucose levels, the greater the risk for the young person to develop symptoms and signs of low glucose levels (hypoglycaemia). This is a particular problem at night. One solution is to develop a system whereby the amount of insulin injected is very closely matched to the blood sugar levels on a continuous basis. In a closed loop system, for example, a continuous glucose sensor communicates with a computer algorithm which drives an insulin pump. The investigators have been developing such a system in Cambridge over the last year with funding from the Juvenile Diabetes Research Foundation. The investigators have found that this system is very effective at preventing hypoglycaemia in young people with diabetes.
Until now the information from the sensor has been entered manually into the computer and the pump settings have also been changed manually. The investigators now need to move onto the next step which is to fully automate the system. The studies will be done in a clinical research facility. The investigators will study the young people on two nights in order to find out if the closed loop system started early in the evening is as effective as when it is started later before sleep. 12 young people will be recruited from diabetes clinics in the East Anglia region. The studies will provide further important information concerning the safety, efficacy and utility of closed loop systems.
| Condition | Intervention |
|---|---|
|
Type 1 Diabetes |
Other: Automated closed-loop insulin delivery |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Open Randomised, Two Period Cross-over Study to Assess the Feasibility, Efficacy and Safety of Automated Closed-loop Glucose Control Initiated at the Time of Dinner or Before Sleep in Children and Adolescents With Type 1 Diabetes |
- The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100). [ Time Frame: midnight to 8:00 am ] [ Designated as safety issue: No ]
| Enrollment: | 16 |
| Study Start Date: | February 2009 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Closed-loops at Dinner
Automated closed-loop control starts at 18:00
|
Other: Automated closed-loop insulin delivery
Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
Other Name: Automated CL
|
|
Active Comparator: Closed-loop at Bedtime
Automated closed-loop control starts at 21:00
|
Other: Automated closed-loop insulin delivery
Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
Other Name: Automated CL
|
Eligibility| Ages Eligible for Study: | 6 Years to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent obtained before study-related activities. Study-related activities are any procedure that would not have been performed during standard medical care.
- The subject is between 6 and 18 years of age (inclusive).
- The subject has type 1 diabetes, as defined by WHO for at least 6 months or confirmed C-peptide negative.
- The subject will have been on insulin pump for at least 3 months
Exclusion Criteria:
- Non-type 1 diabetes mellitus including those secondary to chronic disease
- Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results
- Taking medication likely to interfere with interpretation of the results
- Experienced recurrent severe hypoglycaemic unawareness (as judged by the investigator).
- Known or suspected allergy against insulin.
- Patients with clinical significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator.
Contacts and Locations| United Kingdom | |
| Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital | |
| Cambridge, Cambridgeshire, United Kingdom, CB20QQ | |
| Principal Investigator: | David B Dunger, Professor in Paediatrics | University of Cambridge |
More Information
Additional Information:
Publications:
| Responsible Party: | Dr Roman Hovorka, Principal Research Associate, University of Cambridge |
| ClinicalTrials.gov Identifier: | NCT00989898 History of Changes |
| Other Study ID Numbers: | CI/2008/0036 |
| Study First Received: | October 5, 2009 |
| Last Updated: | June 22, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by University of Cambridge:
|
T1D, closed-loop systems, overnight hypoglycaemia |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013